PDS Biotechnology announces details on two Preclinical influenza presentations

PDS Biotechnology (PDSB) provided updates on preclinical immune response data with a novel, investigational Infectimune based flu vaccine that were featured at the American Association of Immunologists’ IMMUNOLOGY2025 Annual Meeting, which took place May 3-7, 2025, in Honolulu, Hawaii. As previously announced, on Sunday, May 4, 2025, Andrea Sant, Ph.D., Professor of Microbiology and Immunology at the University of Rochester Medical Center, presented “How immune memory from influenza infection shapes protective immune responses to vaccination,” during the International Society of Influenza and Other Respiratory Viruses sponsored symposium. The discussion described how, in preclinical influenza studies, the use of Infectimune resulted in the elicitation of a significantly greater frequency of highly multifunctional, influenza-specific CD4 T cells that produced multiple cytokines compared to current vaccine approaches and also exhibited cytotoxic characteristics. Infectimune was uniquely able to promote CD4 T cells that targeted lung tissue in those with a history of influenza infection.